



IRON INFUSION
AMBULATORY PROGRAM ORDER SET

As of January 2022
PAGE 1 of 3

Allergies: [ ] NKA or \_\_\_\_\_
Weight (Kg): \_\_\_\_\_
Provider Name (please print): \_\_\_\_\_

Required Criteria for Adult Outpatient Administration of Intravenous Iron

- The following criteria must be met, check all that apply.
[ ] Diagnosis of iron deficiency anemia: Hemoglobin (Hgb) level less than 120 g/L in females or less than 130 g/L in males
AND
[ ] Low iron stores as demonstrated by: transferrin saturation (TSAT) less than 20% (0.20) AND/OR ferritin less than 15 mcg/L
OR
[ ] Anemia with chronic kidney disease: TSAT less than 24% (0.24)
AND
[ ] Documented intolerance/inadequate response to appropriate trial of oral therapy OR inability to absorb oral iron.
OR
[ ] Insufficient time (4 weeks or less) to evaluate efficacy of oral therapy for upcoming procedure

Referring Physician/MRP Must Complete the Following Prior to Appointment Being Booked:

- [ ] Patient is receiving Iron as an adjunct therapy to an insured hospital service
OR
[ ] Provide patient with prescription for Iron Sucrose or Iron Isomaltoside and instruct to bring medication to appointment.
[ ] ODB coverage. Prescriber to complete ODB Exceptional Access Program Request for IV Iron Sucrose
If patient is denied ODB coverage and/or does not have third party coverage please contact the Manager of the Ambulatory Program at 613 345 5649 ext. 51261

Medication Orders:

Note if more than a course of therapy is needed (based on maximum dose), after completion of the course of therapy a new order must be submitted with new blood work meeting the above criteria.

\*\*\* All iron doses expressed as elemental iron\*\*\*

IRON ISOMALTOSIDE : (See dosing chart below)

Table with 3 columns: Hgb (g/dL), Dose for weight less than 70 Kg, Dose for weight 70 Kg and above. Rows for Hgb 10 and greater, and Less than 10.

For Patients with chronic kidney disease (Ganzoni formula):

Total iron need (mg) = body weight ^a (Kg) x [target Hgb ^b – actual Hgb (g/dL) x 2.4] + iron stores (mg)^c
a: Use ideal body weight for obese patients (i.e. BMI above 30 Kg/m^2)
b: Target Hgb is 15 g/dL but a lower value may be used based on clinical judgement
c: The iron stores vary from 500 mg to 1000 or use 10 to 15 mg iron/kg body weight

Calculated Iron Isomaltoside Total dose (1 course) \_\_\_\_\_ mg

The cumulative dose can be given as a single IV infusion not exceeding 20 mg/Kg or 1500 mg whichever is lower. If the total cumulative dose exceeds these limits, divide in 2 doses by administering the maximum allowable dose in the 1st administration, if feasible, administer the 2 doses at least one week apart.



**IRON INFUSION  
AMBULATORY PROGRAM ORDER SET**

As of January 2022  
PAGE 2 of 3

- Iron Isomaltoside 1000 mg** in 100 mL normal saline IV, infuse at a max rate of 50 mg/min x 1 dose **OR**
- Iron Isomaltoside 1500 mg** in 250 mL normal saline IV, infuse at a max rate of 50 mg/min x 1 dose **OR**
- Iron Isomaltoside** \_\_\_\_\_ mg in normal saline IV, infuse at a max rate of 50mg/min in divided dose at least one week apart. (Maximum allowable dose will be administered in first visit) as per dosing chart. **OR**
- For fluid restricted patients, give **Iron Isomaltoside** \_\_\_\_\_ mg in 100 mL normal saline IV x 1 dose at a max rate of 50 mg/min.

**Iron Sucrose**

- Iron sucrose 300 mg** in 250 mL normal saline IV infused over 1.5 hours every \_\_\_\_ days x \_\_\_\_ doses
- OR**
- Iron sucrose** \_\_\_\_\_ mg IV in normal saline at a max rate of 140 mg/hr every \_\_\_\_\_ days times \_\_\_\_\_ doses

\*\*\*Maximum total cumulative dose 1000 mg elemental iron administered in 14 days\*\*\*

\*\*Maximum single dose to be given at a time is 500 mg\*\*

\*\*Patients weighing less than 70 kg may require a longer infusion time\*\*

**Maximum 6 doses per course/New order will be required each course**

**Patient Monitoring**

- Vital Signs pre-infusion and q1h during and at least 30 minutes after infusion and PRN
- Hold IV Iron if patient's temperature is above or equal to 37.8 degrees Celsius

**Management of Adverse effects**

- If Adverse Reaction (hypotensive reaction-SBP drop of 25 mmHg, phlebitis and venous spasm, abdominal cramps, leg cramps, nausea, diarrhea)**
- Hold infusion x 30 minutes
- acetaminophen 325 to 650 mg PO q4h PRN
- If symptoms improve resume infusion at half previous rate
- If symptoms persist, give 500 mL normal saline bolus and call physician
- If symptoms persist, call physician

**If Adverse Reaction (anaphylaxis)**

- Stop infusion immediately
- Notify MD
- Start O<sub>2</sub> at 35 to 50% by mask
- diphenhydrAMINE 50 mg IV STAT
- EPINEPHrine (1 mg/mL) 0.5 mL Subcutaneous STAT

**Additional Orders**

<b>Date (yyyy/mm/dd):</b>	<b>Time:</b>	<b>Provider Name (please print):</b>
		<b>Provider Signature:</b>
<b>Date (yyyy/mm/dd):</b>	<b>Time:</b>	<b>Transcriber Name (please print):</b>
		<b>Transcriber Signature:</b>



# IRON INFUSION

## AMBULATORY PROGRAM ORDER SET

As of January 2022

PAGE 3 of 3

PATIENT INFORMATION

**References:**

<sup>1</sup> Iron isomaltoside and iron sucrose. The Ottawa Hospital Parenteral Drug Therapy Manual- 40<sup>th</sup> Edition, 2020

<sup>2</sup> KDIGO. Anemia in CKD [Internet]. Kidney Disease Improving Global Outcomes (KDIGO); 2012 [cited 2019 May 20]. Available from: <https://kdigo.org/guidelines/anemia-in-ckd/>

<sup>3</sup> Iron sucrose product monograph

<sup>4</sup> Iron isomaltoside. UpToDate Accessed on Sept 22<sup>nd</sup> 2020

**FIGURE 1: Algorithm for Iron Deficiency Anemia in Pregnant Women**

